Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.
Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.
As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.
Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."
André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."
About MEndoB
Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.
About Micreos
Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.
For more information, visit www.micreos.com.
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
For more information, please visit www.northwaybiotech.com.
Micreos Contact:
Matt Regan
CEO and Board member, Micreos Pharmaceutical AG
m.regan@micreos.com
Northway Biotech Contact:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Corp. Announces Uplisting to the OTCQB Market14.3.2025 15:00:00 EET | Press release
CALGARY, AB / ACCESS Newswire / March 14, 2025 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company") is pleased to announce that its common shares have commenced trading on the OTCQB Market under the ticker symbol KARX. In addition, the company's common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (DTC). The listing on the OTCQB Market, along with DTC eligibility, is expected to enhance the Company's visibility, simplify the trading process, and improve liquidity for Karbon-X's common shares in the United States, the world's largest capital market. "We are excited to have reached this important milestone and list in the U.S. There is significant demand from United States investors for carbon trading and sequestration technology stories like ours, and we are pleased that it will now be easier for those investors to participate in our growth," said Chad Clovis, CEO of Karbon-X Corp. The OTCQB Market, operat
Formerra Introduces Formerra+ Upgraded Ecommerce Site to Optimize Customer Experience11.3.2025 16:15:00 EET | Press release
Formerra+™ delivers a faster, smarter, and more seamless way to do business with enhanced product search, intuitive navigation, and powerful management tools. ROMEOVILLE, IL / ACCESS Newswire / March 11, 2025 / Formerra, a leader in performance materials distribution, today launched the Formerra+ ecommerce website, now upgraded to deliver a faster, more intuitive, and personalized experience for customers across multiple industries. The enhanced site provides purchasing, engineering, and quality control customers with easy access to ordering and technical information so that they can get the materials they need faster. "Our customers are looking for efficiency, accuracy, and convenience when managing orders and purchasing materials," said Cathy Dodd, Chief Executive Officer at Formerra. "The upgraded Formerra+ online and mobile experience reflects our commitment to delivering the best digital tools and 24/7 ordering experience to customers worldwide." Formerra+ offers simplified naviga
135 Years of Sport Inspiration: U.S. Polo Assn. Hosts Celebration Cup Exhibition and Spring-Summer 2025 Fashion Showcase in Delhi11.3.2025 07:00:00 EET | Press release
WEST PALM BEACH, FL AND NEW DELHI, INDIA / ACCESS Newswire / March 11, 2025 / U.S. Polo Assn. celebrates 135 years of sport inspiration as the official brand of the United States Polo Association (USPA) with a spectacular exhibition game and fashion show in the heart of India's polo capital, Delhi. More than 300 VIP guests attended this milestone event honoring the sport's enduring legacy with a thrilling exhibition match at the iconic Jaipur Polo Grounds, followed by an exclusive U.S. Polo Assn. Spring-Summer 2025 fashion showcase at the luxurious D'Monde Members Club.U.S. Polo Assn. As part of U.S. Polo Assn.'s global moment, this grand event united polo enthusiasts, fashion aficionados, and cultural tastemakers in an event that paid tribute to the sport's rich heritage and longstanding influence. The highlight of the evening was an intense and action-packed exhibition match, where the USPA India Team, led by HH Maharaja Sawai Padmanabh Singh of Jaipur, took on the USPA Global Team w
Shaping Tomorrow: Empowering Women Today - Celebrating International Women's Day 2025 and Advancing Equality for All7.3.2025 01:30:00 EET | Press release
Empowering Women and Girls for a Sustainable Future OTTAWA, ON / ACCESS Newswire / March 7, 2025 / On International Women's Day 2025, the Almas Jiwani Foundation joins global efforts to recognize the remarkable contributions of women and girls worldwide while acknowledging the critical work still required to achieve gender equality. "The empowerment of women and girls is fundamental to achieving a just and peaceful world. As we work toward the Sustainable Development Goals, we must ensure that gender equality is not just an aspiration, but a central tenet of global cooperation. True progress can only be achieved when women and girls are given the rights, opportunities, and platforms to lead, innovate, and contribute to the solutions that will shape our collective future. The United Nations must continue to champion these values, ensuring that the voices of all women are heard, and their potential fully realized in every corner of the globe." - The Honorable Bob Rae, Canadian Ambassador
World of Coffee Geneva 2025 to Showcase 450+ Specialty Coffee Brands, Innovations, and Cutting-Edge Technology June 26-286.3.2025 03:00:00 EET | Press release
A Must-Attend Event Bringing Together 13,000 Coffee Professionals, Enthusiasts, and Innovators from Around the Globe GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / World of Coffee Geneva 2025 marks the final opportunity for companies to exhibit at a Specialty Coffee Association (SCA) trade show in the 2024-2025 cycle, following the wildly successful World of Coffee Dubai, Specialty Coffee Expo (sold out show floor) and World of Coffee Jakarta (sold out show floor). This highly anticipated event will welcome 13,000 international coffee professionals from every part of the specialty coffee value chain, from producers to C-suite executives of large, multinational companies to the Palexpo SA in Geneva, Switzerland, from June 26-28, 2025. "World of Coffee Europe is thriving in a period of remarkable growth, with increasing attendance and a growing number of exhibitors and sponsors recognizing the immense value of in-person engagement," said Yannis Apostolopoulos, CEO of the Special
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom